State Street Corp Purchases 1,157,984 Shares of Standard BioTools Inc. (NASDAQ:LAB)

State Street Corp grew its stake in shares of Standard BioTools Inc. (NASDAQ:LAB) by 26.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,495,136 shares of the company’s stock after buying an additional 1,157,984 shares during the period. State Street Corp owned 1.48% of Standard BioTools worth $10,606,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Hollow Brook Wealth Management LLC bought a new stake in shares of Standard BioTools in the 3rd quarter worth about $10,679,000. Charles Schwab Investment Management Inc. boosted its position in Standard BioTools by 188.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after buying an additional 1,597,728 shares during the period. Bank of New York Mellon Corp grew its stake in Standard BioTools by 1,019.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company’s stock worth $1,736,000 after acquiring an additional 893,383 shares in the last quarter. Royce & Associates LP increased its position in shares of Standard BioTools by 102.0% during the third quarter. Royce & Associates LP now owns 614,552 shares of the company’s stock worth $1,186,000 after acquiring an additional 310,321 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Standard BioTools by 3,691.1% during the second quarter. Rhumbline Advisers now owns 407,467 shares of the company’s stock valued at $721,000 after acquiring an additional 396,719 shares in the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen dropped their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Stock Up 3.8 %

Shares of NASDAQ LAB opened at $1.90 on Friday. Standard BioTools Inc. has a 52 week low of $1.21 and a 52 week high of $3.04. The business’s 50 day moving average price is $1.87 and its 200 day moving average price is $1.92. The firm has a market cap of $707.29 million, a P/E ratio of -2.68 and a beta of 1.61.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.